Empress Therapeutics

United States · Research

Empress Therapeutics is a biotechnology company founded in 2020 and based in Watertown, Massachusetts. The company focuses on accelerating small-molecule drug discovery by integrating genetics, artificial intelligence, and synthetic biology. Empress aims to enhance drug discovery productivity by prioritizing chemistry inherent to human biology, utilizing its Chemilogics™ platform to identify drug candidates with improved safety and efficacy. The Chemilogics™ platform combines genetic data, AI/ML algorithms, synthetic biology, and co-evolution analysis to streamline the discovery process. Empress has over 500 compounds in preclinical development, primarily targeting immune modulation. Its lead candidate is an orally bioavailable small molecule designed to suppress inflammatory cytokines, offering a safer alternative to traditional immunosuppressants. The company plans to advance its candidates into human clinical trials around late 2024. Empress Therapeutics is backed by Flagship Pioneering and actively seeks collaborations with pharmaceutical companies to co-develop its innovative compounds.